ASND vs. JAZZ: Ascendis Pharma vs. Jazz Pharmaceuticals Stock Comparison

Company Profile

Ascendis Pharma (ASND) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ASND is classified in Biotechnology while JAZZ is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Ascendis Pharma (ASND) at 118.78% clears its industry range for ROE, a sharper capital-efficiency signal than Jazz Pharmaceuticals (JAZZ) at 5.05%, which is closer to a typical peer reading.

Ascendis Pharma (ASND) at 70.85% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.

Both Ascendis Pharma (ASND) at 64.98% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Jazz Pharmaceuticals (JAZZ) at 4.88% is closer to the peer norm — faster top-line expansion for ASND.

Only one side can be read here: Jazz Pharmaceuticals (JAZZ) reports EPS growth of -167.51%, ranked against its industry; Ascendis Pharma (ASND) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Ascendis Pharma (ASND) at 2.99 keeps current ratio within its industry’s typical mid-range, while Jazz Pharmaceuticals (JAZZ) at 1.82 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JAZZ.

Ascendis Pharma (ASND) at 0.31 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Ascendis Pharma (ASND) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Ascendis Pharma (ASND) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Ascendis Pharma (ASND) at 19.68 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Ascendis Pharma (ASND) at 16.14 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Jazz Pharmaceuticals (JAZZ) at 3.59 is valued about in line with its industry on P/B ratio, while Ascendis Pharma (ASND) at 10.45 carries an above-peer premium to book — ASND is pricier on assets.

Valuation Metrics